|
(Health-NewsWire.Net, May 14, 2015 ) The report, Global Osteoporosis Drugs Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, and the EMEA and APAC; it also covers the global osteoporosis drugs industry landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.
Osteoporosis, or porous bone, is a disease characterized by low bone density and structural deterioration of bone tissue, leading to fragile bones. As bones becomes fragile, risk of fracture increases. Osteoporosis primarily affects women, but can also affect men. In women, bone loss occurs rapidly in the first few years after menopause and continues through the postmenopausal stage. Osteoporosis progresses when bone resorption occurs too quickly or when replacement is too slow. Risk factors for osteoporosis include gender, age, low body weight, ethnicity, and family history. Some of the risk factors that can be manipulated include sex hormones, medication use, intake of calcium and vitamins, alcohol intake, and smoking.
The analysts forecast global osteoporosis drugs market to grow at a CAGR of 4.14% over the period 2014-2019.
Covered in this report
This report covers the present scenario and the growth prospects of the global osteoporosis drugs market for the period 2015-2019. To calculate the market size, the report considers the revenue generated from the sales of various osteoporosis drugs, including products with approved labeling and generic versions.
The report also presents the vendor landscape and a corresponding detailed analysis of the top vendors in the global osteoporosis drugs market. The vendor landscape section includes a market share analysis of the major vendors along with the performances of their product portfolios. In addition, it discusses the major drivers that influence the growth of the market. It also outlines the challenges faced by vendors and the market at large, as well as the key trends that are emerging in the market. In addition, clinical stage pipeline molecules developed for the treatment of osteoporosis are discussed.
Purchase a Report Copy at http://www.rnrmarketresearch.com/contacts/purchase?rname=378479 .
Key regions
• Americas
• APAC
• EMEA
Key vendors
• Amgen
• Eli Lilly
• Merck
• Novartis
Other prominent vendors
• Abiogen Pharma
• Deltanoid Pharmaceuticals
• F. Hoffmann La Roche
• GlaxoSmithKline
• IMMD
• Ligand Pharmaceuticals
• NPS Pharma
• Pantarhei Bioscience
• Pfizer
• PhytoHealth
• Radius Health
• UPSHER-SMITH LABORATORIES
• Zosano Pharma
Inquire before Buying at http://www.rnrmarketresearch.com/contacts/inquire-before-buying?rname=378479 .
Key Market driver: Increase in aging population
Key Market challenge: Multiple expiries of patents
Key Market trend: Increase in awareness about bone health
Key questions answered in this report
1. What will the market size be in 2019 and what will the growth rate be?
2. What are the key market trends?
3. What is driving this market?
4. What are the challenges to market growth?
5. Who are the key vendors in this market space?
6. What are the market opportunities and threats faced by the key vendors?
7. What are the strengths and weaknesses of the key vendors?
Inquire for Discount @ http://www.rnrmarketresearch.com/contacts/discount?rname=378479 .
About Us:
RnRMarketResearch.com is an online database of market research reports offer in-depth analysis of over 5000 market segments. The library has syndicated reports by leading market research publishers across the globe and also offer customized market research reports for multiple industries.
RnR Market Research
Ritesh Tiwari
1 888 391 5441
sales@rnrmarketresearch.com
Source: EmailWire.Com 
|
